Microtubule stabilising peptides rescue tau phenotypes in-vivo

• Published in: Scientific reports 2016-12, Vol.6 (1), p.38224-38224, Article 38224
• Main Authors: Quraishe, Shmma, Sealey, Megan, Cranfield, Louise, Mudher, Amritpal
• Format: Article
• Language: English
• Subjects: 14/35; 14/63; 631/1647/2198; 631/378/1689; 631/45/612/1228; 64/24; 82/80; Alzheimer Disease - genetics; Alzheimer Disease - metabolism; Alzheimer Disease - prevention & control; Alzheimer's disease; Animals; Animals, Genetically Modified; Axonal transport; Axonal Transport - drug effects; Axonal Transport - genetics; Cell death; Cytoskeleton; Drosophila melanogaster; Humanities and Social Sciences; Humans; Microtubules - genetics; Microtubules - metabolism; Microtubules - pathology; multidisciplinary; Neurodegenerative diseases; Neuroprotection; Peptides; Peptides - pharmacology; Science; Structure-function relationships; Studies; Tau protein; tau Proteins - genetics; tau Proteins - metabolism
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/srep38224

The microtubule cytoskeleton is a highly dynamic, filamentous network underpinning cellular structure and function. In Alzheimer’s disease, the microtubule cytoskeleton is compromised, leading to neuronal dysfunction and eventually cell death. There are currently no disease-modifying therapies to slow down or halt disease progression. However, microtubule stabilisation is a promising therapeutic strategy that is being explored. We previously investigated the disease-modifying potential of a microtubule-stabilising peptide NAP (NAPVSIPQ) in a well-established Drosophila model of tauopathy characterised by microtubule breakdown and axonal transport deficits. NAP prevented as well as reversed these phenotypes even after they had become established. In this study, we investigate the neuroprotective capabilities of an analogous peptide SAL (SALLRSIPA). We found that SAL mimicked NAP’s protective effects, by preventing axonal transport disruption and improving behavioural deficits, suggesting both NAP and SAL may act via a common mechanism. Both peptides contain a putative ‘SIP’ (Ser-Ile-Pro) domain that is important for interactions with microtubule end-binding proteins. Our data suggests this domain may be central to the microtubule stabilising function of both peptides and the mechanism by which they rescue phenotypes in this model of tauopathy. Our observations support microtubule stabilisation as a promising disease-modifying therapeutic strategy for tauopathies like Alzheimer’s disease.